Zofran Lawsuit Parties Propose Master Long and Short Form Complaints, as Federal Birth Defects Litigation Moves Forward, Bernstein Liebhard LLP Reports
The proposed Short Form Complaints were submitted by plaintiffs on June 20th. Again, one complaint is intended to be used for name-brand Zofran lawsuits, while the second is to be utilized by generic plaintiffs. The Short Form Complaint will allow plaintiffs to provide details specific to their individual Zofran lawsuit.
"The use of Master Long and Short Form complaints is standard procedure in a multidistrict litigation, and will streamline the process for filing a claim in this proceeding. We are pleased that the Zofran birth defects litigation is moving forward," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free Zofran lawsuit reviews to families whose children may have been harmed by this medication.
Zofran Birth Defects Allegations
Zofran is an anti-nausea medication that has been approved for use in post-op surgery patients or those undergoing certain cancer treatments. All of the Zofran lawsuits pending in the District of Massachusetts accuse GlaxoSmithKline of concealing hundreds of birth defects reports involving babies who were exposed to the drug in-utero. The complaints also claim that as early as the 1980s, Glaxo was aware of animal studies suggesting that the active ingredient in Zofran could cross the placental barrier in mammals. The placental transfer of Zofran in humans was also confirmed in a study involving 41 pregnancies, according to the lawsuits.
Zofran has never been approved to treat pregnancy-related nausea and vomiting. Yet according to an analysis recently published in the American Journal of Obstetrics and Gynecology, around 1 million expectant women are prescribed the medication or its generic equivalents every year for this purpose. Zofran lawsuits point out that in 2012, GlaxoSmithKline agreed to pay $3 billion to resolve illegal marketing charges with the U.S. Department of Justice that involved a number of its medications. Among other things, the company had been accused of illegally promoting Zofran as an off-label treatment for expectant mothers suffering from pregnancy-related nausea and vomiting.
Children born with birth defects that could be related to their mother's use of Zofran during the first trimester of pregnancy may be entitled to compensation from GlaxoSmithKline. To learn more about filing a Zofran lawsuit, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP